3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
4
Myelodysplastic Syndromes
2
Melanoma
2
Uveal Melanoma
1
Recurrence
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Head and Neck Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Ipilimumab
5
Nivolumab
4
pembrolizumab
3
sargramostim
2
fludarabine
2
binimetinib
2
aldesleukin
2
Interleukin-2
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Cyclophosphamide
2
trametinib
1
tebentafusp
1
sotrastaurin
1
montanide ISA 51
1
incomplete Freund's adjuvant
1
glembatumumab vedotin
1
fludarabine phosphate
1
entrectinib
1
Valproic Acid
1
Tramadol
1
Thalidomide
1
Temozolomide
1
Solutions
1
Ruthenium-106
1
Radiotherapy
1
RNA, Messenger
1
Protein Kinase C
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Ibuprofen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Uveal Melanoma
×
Valproic Acid
×
Clear all
NCT04729543
2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2
Recruiting
20 enrolled